Início › Câncer Colorretal › Carolina do Norte
Ensaios clínicos de Câncer Colorretal em Carolina do Norte
44 estudos para Câncer Colorretal estão buscando participantes em locais em Carolina do Norte.
Cidades em Carolina do Norte
- Durham28 estudos
- Charlotte13 estudos
- Winston-Salem4 estudos
- Asheville3 estudos
- Goldsboro3 estudos
- Concord3 estudos
- Raleigh3 estudos
Texto oficial do estudo (Inglês)
The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
RecrutandoVoluntários saudáveis bem-vindos
Idades de 45 a 75 · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT06995898A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Duke University Medical Center /ID# 279322, Durham
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07525206A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Carolina Cancer Research Center, Wilson
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06270706Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- Wake Forest University Health Sciences, Charlotte
Recrutando
Idades de 65 a 82 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05612347Family Communications After Genetic Testing
- Southeastern Medical Oncology Center-Clinton, Clinton
- CaroMont Regional Medical Center, Gastonia
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- e mais 2
RecrutandoVoluntários saudáveis bem-vindos
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07143487The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Cabarrus/LCI-Concord, Concord
- East Carolina University, Greenville
- e mais 1
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05673148Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- e mais 6
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #12, Durham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05176483Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Duke Cancer Center Cary, Cary
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- e mais 2
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07222800Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- Duke Cancer Center, Durham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05482893A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- University of North Carolina Medical Center /ID# 267786, Chapel Hill
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06820463A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- University of North Carolina at Chapel Hill, Chapel Hill
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06662786Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Duke University Medical Center, Durham
- Duke Cancer Center Raleigh, Raleigh
- Wake Forest University Health Sciences, Winston-Salem
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT05863195A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Local Institution - 0290, Charlotte
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07221357A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213791Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Duke University Medical Center, Durham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06445062Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Duke University School of Medicine, Durham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT05786924A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Messino Cancer Center, Asheville
- The University of North Carolina At Chapel Hill, Chapel Hill
- Oncology Specialists of Charlotte, Charlotte
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT07284849Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Pinehurst
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT07228832Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Duke Cancer Center, Durham
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06252649MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Duke University Medical Center, Durham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT06586515A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
- Duke University Medical Center - Duke Cancer Center, Durham
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT07235293FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Duke University, Durham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT05919264A Study of DM002 in Patients With Advanced Solid Tumors
- Carolina BioOncology Institute, LLC, Huntersville
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT06751329A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT07749586A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
- GSK Investigational Site, Durham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 3 de ago. de 2026 · NCT06885034AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Duke Cancer Center, Durham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT07094113Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #131, Raleigh
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 23 de jul. de 2026 · NCT06974110A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Duke University Hospital, Durham
- Duke University Medical Center, Duke Cancer Center, Durham
- Duke University Medical Center, Durham
- e mais 2
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de jul. de 2026 · NCT05253651Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
- Duke University Medical Center, Durham
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de jul. de 2026 · NCT06937177PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 14 de jul. de 2026 · NCT06896162A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- Duke University Medical Center /ID# 279457, Durham
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 10 de jul. de 2026 · NCT07023289A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Durham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de jun. de 2026 · NCT06835569Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Duke University Medical Center, Durham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 8 de jun. de 2026 · NCT03947385Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Duke Cancer Center, Durham
- Carolina BioOncology Institute, Huntersville
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 3 de jun. de 2026 · NCT06040541Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- Cone Health Cancer Center, Greensboro
- e mais 3
RecrutandoFase 3Voluntários saudáveis bem-vindos
Idades 18 e acima · Todos os sexos · Atualizado em 31 de mar. de 2026 · NCT07018869Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- e mais 21
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06418204Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de fev. de 2026 · NCT07030257Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
- Duke Cancer Institute, Durham
Recrutando
Idades de 18 a 39 · Todos os sexos · Atualizado em 28 de jan. de 2026 · NCT06371768Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.